573 related articles for article (PubMed ID: 10555885)
1. Equivalence of the acute phase reactants C-reactive protein, plasma viscosity, and Westergren erythrocyte sedimentation rate when used to calculate American College of Rheumatology 20% improvement criteria or the Disease Activity Score in patients with early rheumatoid arthritis. Western Consortium of Practicing Rheumatologists.
Paulus HE; Ramos B; Wong WK; Ahmed A; Bulpitt K; Park G; Sterz M; Clements P
J Rheumatol; 1999 Nov; 26(11):2324-31. PubMed ID: 10555885
[TBL] [Abstract][Full Text] [Related]
2. Age adjustment corrects for apparent differences in erythrocyte sedimentation rate and C-reactive protein values at the onset of seropositive rheumatoid arthritis in younger and older patients.
Ranganath VK; Elashoff DA; Khanna D; Park G; Peter JB; Paulus HE;
J Rheumatol; 2005 Jun; 32(6):1040-2. PubMed ID: 15940764
[TBL] [Abstract][Full Text] [Related]
3. Relative contributions of the components of the American College of Rheumatology 20% criteria for improvement to responder status in patients with early seropositive rheumatoid arthritis.
Paulus HE; Bulpitt KJ; Ramos B; Park G; Wong WK;
Arthritis Rheum; 2000 Dec; 43(12):2743-50. PubMed ID: 11145032
[TBL] [Abstract][Full Text] [Related]
4. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis.
Wolfe F
J Rheumatol; 1997 Aug; 24(8):1477-85. PubMed ID: 9263138
[TBL] [Abstract][Full Text] [Related]
5. Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?
El Miedany Y; Youssef SS; El Gaafary M
J Rheumatol; 2006 Mar; 33(3):490-7. PubMed ID: 16511918
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values.
Inoue E; Yamanaka H; Hara M; Tomatsu T; Kamatani N
Ann Rheum Dis; 2007 Mar; 66(3):407-9. PubMed ID: 16926186
[TBL] [Abstract][Full Text] [Related]
7. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study.
Cantini F; Salvarani C; Olivieri I; Macchioni L; Ranzi A; Niccoli L; Padula A; Boiardi L
Semin Arthritis Rheum; 2000 Aug; 30(1):17-24. PubMed ID: 10966209
[TBL] [Abstract][Full Text] [Related]
8. Serum amyloid A in the assessment of early inflammatory arthritis.
Cunnane G; Grehan S; Geoghegan S; McCormack C; Shields D; Whitehead AS; Bresnihan B; Fitzgerald O
J Rheumatol; 2000 Jan; 27(1):58-63. PubMed ID: 10648018
[TBL] [Abstract][Full Text] [Related]
9. Time-course of health status in patients with rheumatoid arthritis during the first year of treatment with infliximab.
Ban A; Inaba M; Furumitsu Y; Okamoto K; Yukioka K; Goto H; Nishizawa Y
Biomed Pharmacother; 2010 Feb; 64(2):107-12. PubMed ID: 19944558
[TBL] [Abstract][Full Text] [Related]
10. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan.
Matsui T; Kuga Y; Kaneko A; Nishino J; Eto Y; Chiba N; Yasuda M; Saisho K; Shimada K; Tohma S
Ann Rheum Dis; 2007 Sep; 66(9):1221-6. PubMed ID: 17369281
[TBL] [Abstract][Full Text] [Related]
11. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.
Pincus T; Strand V; Koch G; Amara I; Crawford B; Wolfe F; Cohen S; Felson D
Arthritis Rheum; 2003 Mar; 48(3):625-30. PubMed ID: 12632413
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
Choy EH; Isenberg DA; Garrood T; Farrow S; Ioannou Y; Bird H; Cheung N; Williams B; Hazleman B; Price R; Yoshizaki K; Nishimoto N; Kishimoto T; Panayi GS
Arthritis Rheum; 2002 Dec; 46(12):3143-50. PubMed ID: 12483717
[TBL] [Abstract][Full Text] [Related]
13. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.
Posthumus MD; Limburg PC; Westra J; van Leeuwen MA; van Rijswijk MH
J Rheumatol; 2002 May; 29(5):883-9. PubMed ID: 12022344
[TBL] [Abstract][Full Text] [Related]
14. Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%-45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States.
Sokka T; Pincus T
J Rheumatol; 2009 Jul; 36(7):1387-90. PubMed ID: 19411389
[TBL] [Abstract][Full Text] [Related]
15. Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity.
Stone M; Fortin PR; Pacheco-Tena C; Inman RD
J Rheumatol; 2003 Oct; 30(10):2112-22. PubMed ID: 14528503
[TBL] [Abstract][Full Text] [Related]
16. Associations between acute phase reactant levels and disease activity score (DAS28) in patients with rheumatoid arthritis.
Yildirim K; Karatay S; Melikoglu MA; Gureser G; Ugur M; Senel K
Ann Clin Lab Sci; 2004; 34(4):423-6. PubMed ID: 15648784
[TBL] [Abstract][Full Text] [Related]
17. The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome.
Devlin J; Gough A; Huissoon A; Perkins P; Holder R; Reece R; Arthur V; Emery P
J Rheumatol; 1997 Jan; 24(1):9-13. PubMed ID: 9002004
[TBL] [Abstract][Full Text] [Related]
18. Associations between the American College of Rheumatology pediatric response measures and the continuous measures of disease activity used in adult rheumatoid arthritis: a secondary analysis of clinical trial data from children with polyarticular-course juvenile idiopathic arthritis.
Ringold S; Chon Y; Singer NG
Arthritis Rheum; 2009 Dec; 60(12):3776-83. PubMed ID: 19950286
[TBL] [Abstract][Full Text] [Related]
19. Activity indices in rheumatoid arthritis.
Villaverde V; Balsa A; Cantalejo M; Fernández-Prada M; Madero MR; Muñoz-Fernández S; Gijón-Baños J; Martín-Mola E
J Rheumatol; 2000 Nov; 27(11):2576-81. PubMed ID: 11093436
[TBL] [Abstract][Full Text] [Related]
20. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.
Buch MH; Seto Y; Bingham SJ; Bejarano V; Bryer D; White J; Emery P
Arthritis Rheum; 2005 Jan; 52(1):42-8. PubMed ID: 15641046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
